Table 6.

Cox-proportional hazard model analysis of factors affecting patient’s progression-free survival or overall survival for clinicopathologic variables and the IHC expression in 92 patients of EOC

Variables	PFS				OS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P
Age (> 60-year-old)	1.777 (0.997-3.169)	0.051			1.844 (0.950-3.579)	0.071
FIGO Stage (III-IV)	2.001 (1.162-3.445)	0.012	1.996 (1.154-3.454)	0.013	2.106 (1.120-3.958)	0.021	1.901 (1.002-3.605)	0.049
Differentiation (poor)	1.450 (1.016-2.071)	0.041			1.365 (0.915-2.037)	0.128
Pathological Subtype (others)	1.250 (0.759-2.058)	0.380			1.193 (0.677-2.103)	0.541
Lymph node metastasis (Yes)	1.701 (1.031-2.807)	0.038			1.836 (1.048-3.218)	0.034
Residual tumor size (> 1 cm)	1.656 (1.024-2.679)	0.040			1.357 (0.784-2.348)	0.276
Lewis y expression (high)	2.276 (1.394-3.716)	0.001	1.931 (1.171-3.185)	0.010	2.338 (1.333-4.100)	0.003	1.878 (1.040-3.389)	0.036
CD44 expression (high)	1.815 (1.120-2.941)	0.016			1.827 (1.055-3.161)	0.031
CD147 expression (high)	1.869 (1.133-3.018)	0.014			2.386 (1.360-4.185)	0.002
HE4 expression (high)	2.247 (1.378-3.663)	0.001	2.012 (1.221-3.315)	0.006	2.424 (1.393-4.219)	0.002	2.071 (1.169-3.671)	0.013
Integrin α5 expression (high)	1.917 (1.180-3.112)	0.009			2.342 (1.340-4.093)	0.003	1.982 (1.117-3.517)	0.019
Integrin β1 expression (high)	2.310 (1.399-3.815)	0.001	2.175 (1.312-3.603)	0.003	2.057 (1.168-3.621)	0.012
Integrin αv expression (high)	1.611 (0.993-2.616)	0.054			1.841 (1.057-3.208)	0.031
Integrin β3 expression (high)	0.966 (0.594-1.570)	0.889			1.022 (0.589-1.772)	0.939

Variables with P < 0.05 in the univariate analysis were included in the multivariate analysis. Abbreviation: PFS, progression-free survival; OS, overall survival; CI, confidence interval; HE4, Human epididymis protein 4.